Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. - Wikidata - wikimedia - TriplyDB

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

http://www.wikidata.org/entity/Q55067769

about

Advances in diagnosis and treatment of metastatic cervical cancer Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications Chinese guidelines on the management of renal cell carcinoma (2015 edition)Molecular Targeted Therapies of Aggressive Thyroid Cancer More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds The treatment landscape in thyroid cancer: a focus on cabozantinib Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial Hürthle cell carcinoma: current perspectives Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma Neoadjuvant Therapy in Differentiated Thyroid Cancer The Treatment of Well-Differentiated Thyroid Carcinoma Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer.A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA.Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer The positive clinical therapeutically effects of Escin on advanced thyroid cancer.Timing of multikinase inhibitor initiation in differentiated thyroid cancer.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance.Differentiated Thyroid Cancer-Treatment: State of the Art.A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study A review of 2014 cancer drug approvals, with a look at 2015 and beyond.A Rare Silent Killer: Right Atrial Metastasis of Thyroid Hürthle Cell Carcinoma.Therapy: Lenvatinib and radioiodine-refractory thyroid cancers.Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis.Lenvatinib and Palbociclib.A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.

P2860

Q26750408-24093095-09C5-4270-80F9-D923948F55A2 Q26751274-074E306A-930B-48E1-BBAB-2D3B4ECE845C Q26765085-2FBE9E6B-FC19-4983-A26F-40432C6F7502 Q26772206-B4D921FE-5870-43D3-92EC-7BACE995B02D Q26774734-8ED3AD8E-D2FA-4E8B-9796-019278EAA6F0 Q26781662-D05F91B5-9C32-4EBA-B630-BE3C514B183C Q26796404-C123A594-38AB-46DB-BF01-87BBD97842A1 Q26829349-88963960-087E-43C0-A45B-CE51610C2F87 Q27853396-1CF01645-61FB-456C-B6B6-82CAFAEC1A01 Q28069765-99FA8FC5-99C7-49B7-A7D8-E9EEABF07E76 Q28070762-8030A609-61B7-40EA-95F2-B11B99AAF08E Q28072655-55A3152E-014E-47FE-841F-9A036DD34621 Q28075305-E2E131D6-2A79-4BE5-BA28-7E609C87BBB3 Q28078879-32431D0C-01CD-4A7D-8550-A412510EFF25 Q28084401-5B344267-8B9E-4577-BC0A-85754A37541E Q30243995-52745636-4F4F-42E1-A7F6-82E01D9CC8C2 Q30249385-9C8B06CA-C5DF-4AAE-8282-7FA42D5F8811 Q30367068-E1D9ACFF-B80A-469E-A6BA-AA806431D5C4 Q31114848-04EE3EAD-B2CC-4C06-B669-42191AD4D455 Q33427289-929B8A0B-64B5-415E-8FC9-2C1F79A64C80 Q33433315-1FB2859D-FA2C-4783-8992-10381DBC97E9 Q33568653-091314AB-2798-46FD-A026-F6D1DD1B1FA6 Q33587905-28187D1B-8D51-4F16-92A2-9A947A7A98C1 Q33607412-677BB36A-E641-438E-A5D3-37B101819708 Q33622678-B13E94EA-C8BD-4369-8CD4-B85332FFB75A Q33679565-2D035E89-35BE-473B-B696-D406E28D417A Q33733408-5DF80714-AE70-4B92-B2F9-EFB06A2EE59F Q33807542-D44B97C8-0456-43B5-8C5D-7B2731EBDB41 Q33819838-CF6096B9-27CA-4507-87EC-A99CE1DD4857 Q33834795-0D0FC4F5-718B-4F5F-A9C3-BA674B6AA9B0 Q33839037-733321BF-3DC2-441C-91EE-20ADAE1E7278 Q33852864-B3452144-EDA4-4FCB-8C89-640F72F5C4B1 Q33885479-B68BD28F-F771-4457-9E82-AE08AA97CE3C Q35170573-15573A2C-8044-44B4-BD3E-2DA02603E4F1 Q35724335-9726B311-30A2-4726-B554-1330EF9CA435 Q35899921-31E6AF8C-FF1B-4DA3-8873-81719524DD07 Q36012586-CFD7D785-7E1C-420A-B0AB-2CB2776776A4 Q36108073-A4A13055-D53F-437C-9508-58B7FEED679B Q36109982-AC17DB56-EB05-490D-84AA-15E1279C099E Q36282782-A87782DD-F212-4C0C-82BA-127E9409B09C

P2860

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

http://www.wikidata.org/entity/Q55067769

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

@en

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

@nl

type

label

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

@en

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

@nl

prefLabel

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

@en

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

@nl

P1433

Q55067769-0BFE5A71-4F0C-42EA-94B7-B6952D85BC00

P1476

Q55067769-2D31700D-358D-404E-9025-EA4274D537DB

P2093

Q55067769-0A34339A-167D-4BB6-9D40-8B4A905F3FD4

Q55067769-134805F9-BF64-4F09-A1E1-F1B16CA89521

Q55067769-15509246-0F7C-4A8E-969A-B2A5FC66D4AF

Q55067769-1F4E7525-AD17-4BB5-ACE1-BEAE29E2E846

Q55067769-23FD6082-7450-4BF7-A7DC-CA3EBDEED367

Q55067769-30CB0EA0-CE63-473A-BA80-80D8D046E2B8

Q55067769-31662760-C68F-4890-8F01-E8DAC702A57F

Q55067769-4CE8CF1F-A1D9-4437-9324-189B8E98A931

Q55067769-59C5E880-6A95-46AA-99FB-C7D88F5532A1

Q55067769-AD7D623A-E1CF-4C5F-B576-31ECEB2205D6

P304

Q55067769-B2C631F4-6EB9-4F78-A65C-33106F2CFC07

P31

Q55067769-8C40039F-6D02-4C6C-9334-37FD16EA10C6

P356

Q55067769-F1D29354-4DF8-4F42-9690-D4E7DAC97D8D

P407

Q55067769-58ABBAE3-A5A0-4D49-BF20-2F38B1BC38DC

P433

Q55067769-788E46E3-A59E-41A8-B032-75C2046A73A0

P478

Q55067769-6FE39FD5-98FD-4B18-8670-CB6338204ED7

P50

Q55067769-2BFC72C9-56FC-4AFE-AC62-6C0211E6DE51

Q55067769-39F35CCB-4836-4EB1-93BA-7802E756A1F1

Q55067769-528299D7-87AB-4E40-979E-D17FFA03815A

Q55067769-B565CF7B-D633-45C0-B83A-F914FD8D9E0E

Q55067769-F0EB2152-C59A-4D56-9464-8DADAD03242E

P577

Q55067769-759F1927-8A17-4DEA-AA5D-8585AFBC72A1

P698

Q55067769-E21DA47D-FBCA-40A3-9823-EF703D03AC45

P921

Q55067769-0378F7C3-1B43-4E98-8FBC-2F895F691CB3

P356

P1433

The New England Journal of Medicine

P1476

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

@en

P2093

Ana O Hoff

http://www.w3.org/2001/XMLSchema#string

Andrew G Gianoukakis

http://www.w3.org/2001/XMLSchema#string

Begoña de las Heras

http://www.w3.org/2001/XMLSchema#string

Bruce Robinson

http://www.w3.org/2001/XMLSchema#string

Corina E Dutcus

http://www.w3.org/2001/XMLSchema#string

Junming Zhu

http://www.w3.org/2001/XMLSchema#string

Kate Newbold

http://www.w3.org/2001/XMLSchema#string

Lori J Wirth

http://www.w3.org/2001/XMLSchema#string

Makoto Tahara

http://www.w3.org/2001/XMLSchema#string

Manisha H Shah

http://www.w3.org/2001/XMLSchema#string

P304

621-630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1406470

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P50

Steven I. Sherman

Monika K Krzyzanowska

Mouhammed Amir Habra

Rossella Elisei

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25671254

http://www.w3.org/2001/XMLSchema#string

P921